NeuroNEXT at SNI
NeuroNEXT at Swedish Neuroscience Institute (SNI) is one of only two Pacific Northwest sites for a nationwide consortium of 25 centers that conduct clinical trials for patients with diseases of the nervous system. The NeuroNEXT consortium is sponsored by the National Institute of Neurological Disorders and Stroke.
NeuroNEXT Clinical Trials
May 2014 - NN101 SMA Study Healthy Enrollment Complete: The Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development study has completed enrollment of healthy babies in the control group, but still has openings for SMA babies. Swedish Neuroscience Institute is a referring site for this study.
May 2014 - NN102 SPRINT MS Study Open at SNI: The SPRINT-MS study, "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis," is now open at SNI. Dr. Pavle Repovic of the Swedish Multiple Sclerosis Center is the study Principal Investigator. The goal of this study is to determine the safety and tolerability of the drug ibudilast (also called MN-166) in patients with primary and secondary progressive Multiple Sclerosis. Enrollment is open. For more information contact us at email@example.com or call Becky Wood, NeuroNEXT Site Coordinator, at 206-320-7115.
May 2014 - NeuroNEXT Opens Studies NN103 and NN104: Study NN103 is "A Phase II Trial of Rituximab in Myasthenia Gravis," while study NN104 is a "Safety Evaluation of 3K3A-APC in Ischemic Stroke." The NN103 trial looks at the drug rituximab as another non-steroidal agent in managing Myasthenia Gravis. NN104 evaluates the safety of study drug 3K3A-APC used in conjunction with the clot-busting drug tPA in patients who have had an ischemic stroke. The study drug should minimize some of the possible side-effects of tPA, which include treatment-related bleeding. SNI is a referring site for both of these studies.
Information on these NeuroNEXT studies, as well as other clinical trials being done in the United States, can be found at the ClinicalTrials.gov Web site.
"Developing Early-Stage Clinical Trials" was the title of the 2014 Research Investigator Training Symposium presented on March 25th. More than 40 people attended the day-long session, which covered ground-level information on starting a clinical trial. Topics included statistics, funding, ethics of placebo and comparator arms, generating pilot data, defining early-stage clinical trials, and regulatory compliance. The symposium, worth several hours of Continuing Medical Education credit, was recorded and can be accessed by going to the Swedish CME Archives. The recorded symposium features video of each speaker with the slide set synchronized with the talk. Funding for this symposium came from NeuroNEXT.
Clinical Trials Pipeline
Dr. John W. Henson is the chair of the Pipeline Development Committee of the NeuroNEXT Consortium. The Committee is developing a program to attract small and medium pharmaceutical companies to NeuroNEXT to have the consortium develop clinical trials needed for drug development. The Committee is currently working on developing a social media presence and offering a free clinical-trial consultation to interested pharmaceutical companies. The consultations will be courtesy of the CNS Accelerator Group, which is an ad-hoc group of experienced clinical trial investigators willing to share their expertise and experience in developing clinical trials. The group is currently a work in progress. Contact Becky Wood at 206-320-7115 or at firstname.lastname@example.org for more information on the Clinical Trials Pipeline Committee or the CNS Accelerator Group.
NeuroNEXT at Swedish Neuroscience Institute is led by Vice President of Medical Affairs, John W. Henson, MD, FAAN, MBA. Becky Wood is the NeuroNEXT Site Coordinator. For more information, email email@example.com or call 206-320-7115. You can find more information about the NeuroNEXT consortium at http://www.neuronext.org/.
Become a NeuroNEXT Affiliate
NeuroNEXT at Swedish Neuroscience Institute is establishing a network of affiliate neurologists and neurosurgeons to participate in NeuroNEXT studies. As a NeuroNEXT affiliate, you will receive occasional emails about upcoming clinical trials, especially regarding the need for study subjects. Affiliate status is open to neurologists and neurosurgeons in the Washington, Wyoming, Alaska, Montana, and Idaho regions.
Note: The information in this form will be used only for informational purposes related to the NeuroNEXT consortium and will not be provided or sold to any other party or organization.